DEA raises 2026 production quotas for hydromorphone, amphetamine and methylphenidate after FDA shortage reports
Published November 15, 2026 · Coverage November 8–14, 2026, Pacific · Lower priority
The Drug Enforcement Administration (DEA) issued a final order, effective November 10, 2026, raising the 2026 aggregate production quotas (APQ) for d,l-amphetamine, d-amphetamine (for sale), hydromorphone and methylphenidate (for sale). For hydromorphone, DEA found that multiple manufacturers had reported a domestic shortage of hydromorphone hydrochloride injectable products, and it raised the APQ from 1,949,378 grams to 2,356,798 grams. DEA published the order without a comment period to meet the 30-day review timeframe for schedule II drugs on the Food and Drug Administration (FDA) shortage list.
Background
DEA sets yearly production quotas for schedule I and II controlled substances, and it published the established 2026 quotas on January 5, 2026 (91 FR 287). When a manufacturer asks for more quota for a schedule II drug on FDA's shortage list, the law requires DEA to complete its review within 30 days.
Who this affects
Hospital pharmacies and supply chain teams managing hydromorphone injectable and stimulant shortages.
Why it matters
Inference: more quota allows manufacturers to make more hydromorphone, which may ease the injectable shortage over time; it does not by itself restore supply, so hospital shortage protocols and substitution plans stay in place.
Recommended action
- Pharmacy and supply chain: keep hydromorphone injectable shortage protocols active and track supplier allocations for any change.
Scope and timing
- Authority status
- Final
- Responsible owner
- Pharmacy; Supply Chain
- Publication date
- 2026-11-10
- Effective date
- 2026-11-10
- Other dates
- Signed 2026-11-04; issued without a comment period
Not established
Current FDA shortage status for hydromorphone injection was not checked.
Sources
Complete edition and supplemental material
This article in the complete report →
Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.
Read the entire Compliance Sweep report →